{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041596","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.535645+00:00","generated_at":"2026-06-11T15:12:44.345541+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"HCW Biologics Q2 net loss widens to $4.3M; secures $26.3M line of credit","bullets":["Q2 2023 revenue $622,807 from licensed molecule sales to Wugen, down sharply from $3.6M in H1 2022; Wugen expected to limit purchases in 2023.","Net loss $4.3M in Q2 2023 vs $3.5M in Q2 2022; H1 net loss $9.4M vs $5.6M.","G&A expenses up 76% to $3.0M, driven by legal fees from Altor/NantCell arbitration.","Secured $26.3M development line of credit with Prime Capital Ventures, maturity April 2028; construction permits for new HQ obtained.","Cash and equivalents $17.4M as of June 30, 2023; expects to fund operations to Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041596","json":"https://secwatch.observer/filing/0000950170-23-041596.json","markdown":"https://secwatch.observer/filing/0000950170-23-041596.md","text":"https://secwatch.observer/filing/0000950170-23-041596.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000095017023041596/0000950170-23-041596-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000095017023041596/hcwb-20230811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T15:12:44.345541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc10b93d6ba091f3fd49afce9668843ff00b03b9","claim":"HCW Biologics Inc. reported second quarter ended June 30, 2023 results: revenue $622,807, net income $4.3 million.","evidence_excerpt":"gastric cancer, urothelial carcinoma, and melanoma. 2 Second Quarter 2023 Financial Results: • Revenues: Revenues for the quarter ended June 30, 2022 and 2023 were $454,000 and $622,807, respectively. Revenues for the six months ended June 30, 2022 and 2023 were $3.6 million and $664,690, respectively. Revenues were derived exclusively from the sale of licensed","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828673/000095017023041596/0000950170-23-041596-index.htm","confidence":0.82,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$622,807"},{"label":"Net income","value":"$4.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}